The Priority Review

The stream · Daily digest

The stream: Tuesday, October 20, 2026

7 briefs from FDA, ClinicalTrials.gov and the Federal Register, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 3

  1. Amgen and AstraZeneca report Phase 3 CROSSING trial results for TEZSPIRE in eosinophilic esophagitis

    The Phase 3 CROSSING trial showed TEZSPIRE achieved histologic remission in 64.8% (210 mg) and 68.9% (420 mg) of patients at week 24 versus 3.5% on placebo (p<0.001). The Dysphagia Symptom Questionnaire score decreased by 18.8 points (210 mg) and 22.0 points (420 mg) versus 14.7 points on placebo, with reductions sustained through week 52.

    Source: Company press release (PR Newswire), October 20, 2026

  2. GC Biopharma registers Phase 2/3 trial of GC3114B in adults 65 years or older

    The study plans to enroll 1806 participants and is expected to begin in October 2026. It is a multicenter, randomized, double-blind, active-controlled trial that will evaluate the safety of GC3114B and assess whether its immune response is non-inferior to that of the active control.

    Source: ClinicalTrials.gov registry record, October 20, 2026

  3. Janssen posts results of Phase 3 ustekinumab trial in pediatric ulcerative colitis

    The study, completed in 2025, enrolled 112 pediatric participants with moderately to severely active ulcerative colitis and evaluated ustekinumab induction and maintenance therapy. Results were first posted on ClinicalTrials.gov on October 20, 2026.

    Source: ClinicalTrials.gov results record, October 20, 2026

Approvals · 2

  1. FDA approves once-weekly generic hormone therapy patch for women

    The FDA approved the first generic of Climara Pro, a transdermal estradiol and levonorgestrel system (0.045 mg per day/0.015 mg) applied once a week for women with an intact uterus. The generic is therapeutically equivalent to Climara Pro and the most common adverse reactions are application site reaction, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome (≥5 %).

    Source: FDA press announcement, October 20, 2026

  2. FDA approves first-of-its-kind chronic hepatitis B treatment

    The FDA approved Hibsago (bepirovirsen) injection for adults without cirrhosis who have been on antiviral therapy for at least six months and have HBsAg levels of 3,000 IU/mL or less. The approval includes the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic.

    Source: FDA press announcement, October 20, 2026

Regulation · 2

  1. FDA issues final guidance on prescription drug apps and software

    The FDA released final guidance on October 20, 2026 that clarifies when app content is subject to FDA submission requirements and when it should be mentioned on a drug's official label. The guidance identifies two categories of companion software-apps connected to a medical device and standalone apps-and sets conditions for labeling and what companies should submit to the agency.

    Source: FDA press announcement, October 20, 2026

  2. FDA releases guidance on new dietary ingredient notifications

    The Food and Drug Administration announced the availability of final guidance titled "New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Information About the NDI: Guidance for Industry." The guidance addresses frequently asked questions and provides recommendations for manufacturers and distributors on the identity and safety information that should be included in an NDIN.

    Source: Federal Register notice, October 20, 2026